Physician profile
Marco Pappagallo
NPI 1720069610
$35,628.70
in general payments reported to CMS, 2019-2025
10 companies · $94.77 in 2025
The $94.77 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $670 · 2021: $4,881 · 2022: $8,518 · 2023: $21K · 2025: $94.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $21K · Food and Beverage: $94.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $21,318.42 |
| Food and Beverage | $94.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $21,318.42 | 2023 | Qutenza |
| Grt US Holding, INC. | $11,710.80 | 2020-2022 | |
| Biodelivery Sciences International, INC. | $2,307.82 | 2020-2021 | |
| Medtronic USA, INC. | $120.73 | 2019 | |
| Pfizer INC. | $83.46 | 2021-2025 | |
| Axsome Therapeutics, INC. | $24.59 | 2025 | Symbravo |
| Boston Scientific Corporation | $19.35 | 2020 | |
| Depuy Synthes Sales INC. | $16.71 | 2021 | |
| Vertical Pharmaceuticals, LLC | $15.19 | 2019 | |
| Allergan, INC. | $11.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marco Pappagallo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.